Effect of pregnane X receptor and cytochrome P450 oxidoreductase gene polymorphisms on trough concentrations of rivaroxaban and edoxaban in patients with nonvalvular atrial fibrillation

Eur J Clin Pharmacol. 2023 May;79(5):703-705. doi: 10.1007/s00228-023-03483-7. Epub 2023 Mar 23.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Anticoagulants / therapeutic use
  • Atrial Fibrillation* / drug therapy
  • Atrial Fibrillation* / genetics
  • Cytochrome P-450 Enzyme System
  • Factor Xa Inhibitors / therapeutic use
  • Humans
  • Pregnane X Receptor / genetics
  • Rivaroxaban / therapeutic use
  • Stroke*

Substances

  • Rivaroxaban
  • edoxaban
  • Pregnane X Receptor
  • Cytochrome P-450 Enzyme System
  • Anticoagulants
  • Factor Xa Inhibitors